ArticleBMC cardiovascular disorders2023
Relationship between serum interleukin-6 levels and severity of coronary artery disease undergoing percutaneous coronary intervention.
Article in BMC cardiovascular disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03075566 (Clinical and Biochemical Markers in Coronary Artery Disease), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical and Biochemical Markers in Coronary Artery Disease
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Article
- The association between plasma inflammatory, oxidant, and antioxidant status with cardiometabolic indices and coronary artery stenosis in participants undergoing coronary angiography: a case-control study.BMC cardiovascular disorders · 2026Article
- Innovations in Diagnosis and Treatment of Coronary Artery Disease.Diagnostics (Basel, Switzerland) · 2025Review
- Risk factors for coronary artery disease progression: A retrospective cohort study of clinical and biochemical predictors.Medicine · 2025Observational
- Role of interleukins in the pathogenesis of coronary heart disease: A literature review.World journal of cardiology · 2025Review
- Predictive Value of Selected Plasma Biomarkers in the Assessment of the Occurrence and Severity of Coronary Artery Disease.International journal of molecular sciences · 2025Article
- Platelet-Leukocyte Aggregate and Interleukin-6: An Emerging Perspective on a New Diagnostic and Therapeutic Clue for Acute Coronary Syndrome, A Case-Control Study.Health science reports · 2024Article
- Coronary Artery Plaque Phenotype and 5-Year Clinical Outcomes in Older Patients with Non-ST Elevation Acute Coronary Syndrome.Reviews in cardiovascular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCytokines play a potential role in atherosclerosis pathogenesis and progression. We investigated the association of interleukin-6 (IL-6) with the angiographic severity of coronary artery disease (CAD).
methodsThree hundred ten angiografically diagnosed CAD patients and 210 controls were enrolled in this study. CAD patients were stratified according to IL-6 cut-off value into high levels IL-6 group (≥ 9.5 pg/mL) and low levels IL-6 group (< 9.5 pg/mL). The severity of CAD was assessed according to Gensini score (GS), artery stenosis degree and the number of vessels involved. The mean age was 60.3 ± 11.0 years.
resultsThe level of IL-6 in patients was increased compared to controls and ranged from 1.5 to 3640.0 pg/mL. High levels of IL-6 were significantly associated with high levels of GS (> 40) but not with stenosis degree and vessel score. GS levels were significantly more elevated in patients with high levels of IL-6 group than in low IL6 levels patients (60.6 ± 39.5 vs 46.7 ± 37.2; p = 0.027). The analysis of the ROC curve performed in myocardial infarction patients showed that IL-6 (AUC: 0.941 (CI 95% 0.886, 0.997; p < 0.001) could be a powerful predictor marker in evaluating the infarct size after myocardial infarction when compared to myonecrosis biomarkers.
conclusionsIL-6 levels were associated with the severity of CAD assessed by the GS. Based on the highest levels of IL-6 measured in patients with STEMI, our study strongly suggests that IL-6 could be a powerful marker in evaluating the myocardial necrosis.
trial registrationClinicalTrials.gov Number: NCT03075566 (09/03/2017).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.